# PreComb Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precomb-therapeutics

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.precomb.com
- Total disclosed funding: $2.4M
- Latest round: Seed (Apr 26, 2021)
- Investors on record: 3

## About

Based in Switzerland, PreComb Therapeutics AG specializes in precision oncology, utilizing innovative 3DTwin® technology to create patient-derived 3D tumor models that closely replicate actual cancer microenvironments for enhanced drug testing.PreComb Therapeutics AG is engaged in developing precision oncology solutions through advanced tumor modeling techniques. Founded in 2018, the company is headquartered in Switzerland. Jens Kelm, the founder, has a history of innovation in the biotech sector. As of December 30, 2024, the company has completed 3 distinct funding deals, with the latest round raising CHF 1.3 mn through participation from investors including Kinled Holding and LongeVC. This round represents the total amount raised to date, which stands at CHF 1.3 mn.PreComb is focused on advancing precision oncology through its innovative 3DTwin® technology, which generates patient-derived 3D tumor models that closely mimic real cancer microenvironments. These models facilitate more effective drug testing, accelerate research timelines, and enhance treatment outcomes by enabling targeted therapies tailored to individual cancer profiles. The company addresses significant challenges in oncology, such as the need for more accurate drug response predictions and the reduction of side effects associated with cancer treatments. PreComb primarily serves researchers, pharmaceutical companies, and academic institutions, providing them with a robust platform for drug discovery and development. Their products are utilized in major markets, including Switzerland and Germany, where leading clinics and research facilities leverage these advanced tumor models for clinical and preclinical applications.PreComb's revenue model is built around partnerships and collaborations with various stakeholders in the biotechnology and pharmaceutical sectors. The company engages in B2B transactions, offering access to its 3DTwin® technology and related services to research institutions and pharma companies. These partnerships typically involve tailored contracts that allow clients to utilize PreComb's automated screening platform for standardized and reproducible drug testing. While specific pricing plans are not disclosed, the revenue structure is likely based on subscription agreements or project-based fees that reflect the complexity and scale of the services rendered. Revenue generated from these transactions supports the ongoing research and development of their innovative tumor modeling solutions, ensuring continuous refinement and validation of their offerings.In December 2024, PreComb Therapeutics AG raised an undisclosed amount of venture funding led by Koodos Limited. The company will use this funding to support business growth and product commercialization. Plans are underway for launching new products designed to enhance their 3DTwin® technology and expand into additional markets across Europe, targeting greater accessibility for their advanced tumor models by the end of 2025.

## Funding rounds

- Seed, Apr 26, 2021, $2.4M — FiveT Capital, High-Tech Gruenderfonds, Kinled Holding

## Investors

- FiveT Capital — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- Kinled Holding — Seed